Kaleido: Rises on starting inflammatory bowel disease therapy study

Kaleido Biosciences

30/09/2020 16:24

** Kaleido Biosciences Inc's shares  KLDO.O  rise 9.03% to
$11.11
    ** Drug developer doses first patient in a clinical study
evaluating its therapy candidate for patients with
mild-to-moderate ulcerative colitis - an inflammatory bowel
disease  urn:newsml:reuters.com:*:nGNX4KSrm9
    ** Evidence suggests a feature of ulcerative colitis is an
alteration of the gut microbiome - KLDO
    ** Says its candidate, KB295, is a microbiome metabolic
therapy designed to drive the function and distribution of the
gut's existing microbes
    ** KLDO stock up ~122% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))